US5286848A - Lanthanide cryptate of trisphenanthroline - Google Patents

Lanthanide cryptate of trisphenanthroline Download PDF

Info

Publication number
US5286848A
US5286848A US08/051,819 US5181993A US5286848A US 5286848 A US5286848 A US 5286848A US 5181993 A US5181993 A US 5181993A US 5286848 A US5286848 A US 5286848A
Authority
US
United States
Prior art keywords
phenanthroline
group
cryptate
functional group
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/051,819
Inventor
Katsu Honzawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamamatsu Photonics KK
Original Assignee
Hamamatsu Photonics KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamamatsu Photonics KK filed Critical Hamamatsu Photonics KK
Priority to US08/051,819 priority Critical patent/US5286848A/en
Application granted granted Critical
Publication of US5286848A publication Critical patent/US5286848A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • Y10S530/83Plasma; serum

Definitions

  • the present invention relates to a novel lanthanide chelate compound, and more particularly a lanthanide complex of phenanthroline cryptand in which lanthanide ion is occluded in the cavity of the cryptand.
  • the compound is stable and photo active and usable for immunoassay or photosynthesis when it is combined with a variety of substrates.
  • An object of the present invention is to provide a novel lanthanide complex of the cryptand of the formula (I') described below.
  • Another object of the present invention is to provide a new photoactive material labelled with the lanthanide complex of the cryptand of the formula (I') described below.
  • FIG. 1 shows a schematic, steric view of the principal cryptate of the present invention
  • FIG. 2A shows an explanatory view of energy level transition of lanthanide ion
  • FIG. 2B shows an explanatory view of energy level transition of cryptate.
  • the cryptate of the present invention has a steric structure shown in the FIG. 1 where lanthanide ion is occluded in the cavity of the cryptand of three phenanthroline (i.e. 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline), which cryptand is referred simply to mere "cryptand", and is extremely stable.
  • phenanthroline i.e. 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline
  • a lanthanide ion itself, in general, when exposed by light energy, the initial energy level (S) increases to level (S) and then decreases to the triplet energy level (T) to effect emission, and thus is evaluated as delayed time fluorescenser.
  • the increased level (S) decreases to lanthanide energy level (D) via (T) and then effects emission, wherein the energy level (F) is the ground state of lanthanide ion.
  • the lanthanide ion used in the present invention is any one, though europium, terbium, samarium and dyspridium are desirable in this order due to their emission ability.
  • the cryptate shown by the FIG. 1 solves the problems seen in the conventional coordination compounds, that is, ease of the release of metal atom from the ligand, the tendency of putting out of the fluorescence emission and the low energy transition efficiency on the ligand.
  • the novel cryptate of the present invention can be easily prepared by slightly modifying the aforementioned method of Rodriguez et al which is incorporated by reference herein.
  • the cryptand prepared according to the Rodriguez's method is allowed to react with a strong acid salt of lanthanides such as nitric acid salt.
  • the cryptand and cryptate each having an aromatic ring group such as a phenyl group can also be obtained from the phenanthroline compound.
  • the cryptate derivative having the functional group can be prepared by introducing a functional group capable of bonding directly or indirectly to a --NH 2 group or --SH group at any position of the aromatic ring group contained in the cryptand.
  • a functional group capable of bonding directly or indirectly to a --NH 2 group or --SH group at any position of the aromatic ring group contained in the cryptand By the introduction the cryptate of the present invention can considerably enlarge its use, permitting covalently bonding with a substrate such as a high molecular weight substance having a --NH 2 or --SH group, for example, proteins, especially antibodies, a polymer and the like.
  • the combined substance can be used in a fluorescent immunoassay or light modification.
  • the functional group is selected, for example, from halosulfonyl, haloacetamido, ethyleneiminosulfonyl, maleimido, isothiocyanato groups and the like which can be covalently bonded with amino or sulfhydryl group.
  • a cryptate containing a phenyl group substituent is preferable for the purpose.
  • the functional group may be one capable of bonding to the substrate through a bifunctional compound.
  • amino group is, for example, selected therefor.
  • the example of the bi-functional compound for amino group is a water soluble carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, glutaraldehyde, or bis-diazotized benzidine.
  • the bonding technique to the substrate is well known as a method of bonding a hapten such as polypeptide to a carrier protein for giving the hapten an antigenicity.
  • the functional group introduced is sufficient in an amount of 1 per mol of cryptate but may be more.
  • the introduction of the functional group to an aromatic ring of a coordination compound or photoactive compound is well known.
  • C. F. Meares and T. Wensel disclose the reduction of (p-nitrobenzyl-ethylenediamine tetraacetic acid to (p-amino-benzyl) compound of which amino group is then converted to a isothiocyanato group by reacting with thiophosgen and to haloacetamido group by haloacetohalide, respectively.
  • J. K. Weltman et al J. Biol. Chem., vol.
  • N-(3-pyrene) maleimide by reacting 3-aminopyrene with maleic anhydride to form N-(3-pyrene) maleamic acid which is then cyclized under dehydration by reacting with acetic anhydride to form N-(3-pyrene) maleimide.
  • W. H. Scouten et al (Biochimica et Biophysica Acta, 336, 1977, pp 421-426) report the preparation of N-dansylaziridine by reacting dansyl chloride with ethylenimine in the presence of triethylamine. All of the references are incorporated by reference herein.
  • any method including the above methods may be used.
  • a phenyl group with which phenanthroline is substituted is more easily subjected to such introduction, and the use of phenanthroline compound having a phenyl substituent is desirable.
  • the introduction of functional group may be effected with respect to phenanthroline or phenylphenanthroline compound itself, cryptand or cryptate thereof.
  • phenanthroline compound or its cryptand would be subjected to such introduction.
  • the number of the functional group would be optionally selectable.
  • the kind of functional group is suitably selected depending upon the kinds of bonding objective amino or sulfhydryl group in a substrate to be bonded.
  • the objective high molecular weight substance is an antibody
  • a halosulfonyl such as chlorosulfonyl group or isothiocyanate group is selected for IgG having an objective amino group in the side chain and a haloacetamide such as iodoacetamide, or ethyleneiminosulfonyl or maleimino group for Fab' having a sulfhydryl group.
  • an amino group is introduced if a bifunctional compound such as glutalaldehyde or others as mentioned above is used for the substrate having a free amino group.
  • the present invention provides a functional cryptate derivative of the formula ##STR3## wherein Y is a functional group capable of directly or indirectly bonding to amino or sulfhydryl group, which may be amino, isothiocyanato, halosulfonyl, halo-acetamido, maleimido, ethyleneiminosulfonyl group, or a phenyl group having the same, and the total number of "m" is at least 1 and each "m" is 0, 1 or 2.
  • the present cryptate is soluble in water.
  • the cryptate itself can be used as a wave length modifier in a form embedded in a polymer film, sheet or beads or photo synthesizer.
  • the cryptate derivative having the functional group can be bonded with a variety of high molecular weight substances to form a permanent photoactive material.
  • an antibody labelled with the present cryptate derivative is usable for delayed time performance fluorescent immunoassay.
  • the labelled antibody is dissolved in water or immobilized on solid as carrier and may be used in immunoassay and affinity chromatography.
  • covalently labelled polymer is usable as a wave length modifying film for ultraviolet ray sensivity in silicon photodiode and CCD camera or as a light absorption film.
  • reaction liquid After cooling to a room temperature, the reaction liquid is filtered and dried to obtain 0.25 mmol 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-diphenyl-1,10-phenanthroline) europium.
  • Example 2 2 mmol 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-dichlorosulfonylphenyl-1,10-phenanthroline) europium obtained in Example 1 is dissolved in 0.5 ml of ethanol and added drop by drop slowly to a carbonate buffer solution (100 mmol, pH 9.2) containing 0.72 mol bovine serum albumin(BSA). The reaction liquid is subjected to an affinity chromatography using sephadex-5 column to obtain the labelled BSA which is excited by light of 337 nm and confirmed by the fluorescece at 613 nm based on europium ion, by means of a fluorescence photometer.
  • a carbonate buffer solution 100 mmol, pH 9.2
  • bovine serum albumin(BSA) 0.72 mol bovine serum albumin
  • Example 1 is repeated to obtain 2,2',2",9,9',9"-bis-[nitrilotri(methylene)]tris (1,10-phenanthroline) europium, provided that 2,9-dimethyl-1,0-phenanthroline is used in place of 4,7-diphenyl-2,9-dimethyl-1, 10-phenanthroline.

Abstract

A photoactive lanthanide complex of 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline) and its functional derivative capable of bonding with substrate such as polymer and protein are provided. The lanthanide complex is usable for photosynthesis and photoimmunoassay.

Description

This is a continuation of application Ser. No. 07/519,594, filed on May 7, 1990, which was abandoned upon the filing hereof.
BACKGROUND OF THE INVENTION
The present invention relates to a novel lanthanide chelate compound, and more particularly a lanthanide complex of phenanthroline cryptand in which lanthanide ion is occluded in the cavity of the cryptand. The compound is stable and photo active and usable for immunoassay or photosynthesis when it is combined with a variety of substrates.
Hitherto, a coordination compound of lanthanide ion such as europium and terbium ions has been reported, as a desirable photoimmunoassay labelling agent due to its emission sharpness and ability of delayed time performance. For example, Ilkka Hemmila et al, Analytical Biochemistry, Vol. 137, pp 335-343 (1984) disclose chelate compounds of Eu with a variety of beta-diketones, L. M. Vallarino et al, "Automation Cancer Cytology and Cell Image Analysis" pp 31-45 (1979) edited by N. J. Pressman, disclose octa-coordinate Eu(III) compound containing three beta-ketonato ligands and one ortho-phenanthroline ligand. Further, Juan-carlos Rodrigez-Ubis et al, Helv. Chim. Acta, Vol. 67 pp 2264-2269, report an NaBr complex of a cryptand, 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline) of the formula, ##STR1##
An object of the present invention is to provide a novel lanthanide complex of the cryptand of the formula (I') described below.
Another object of the present invention is to provide a new photoactive material labelled with the lanthanide complex of the cryptand of the formula (I') described below.
SUMMARY OF THE INVENTION
According to the present invention, there is provided a lanthanide complex of 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline), of the following formula, designated formula (I'), which complex may otherwise be referred simply to as "cryptate" herein, ##STR2## wherein X denotes a hydrogen atom or a phenyl group and the total number of "n" is at least 1 and each "n" is 0, 1 or 2 when X is a phenyl group.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows a schematic, steric view of the principal cryptate of the present invention;
FIG. 2A shows an explanatory view of energy level transition of lanthanide ion; and FIG. 2B shows an explanatory view of energy level transition of cryptate.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The cryptate of the present invention has a steric structure shown in the FIG. 1 where lanthanide ion is occluded in the cavity of the cryptand of three phenanthroline (i.e. 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline), which cryptand is referred simply to mere "cryptand", and is extremely stable.
As shown in FIG. 2A, a lanthanide ion itself, in general, when exposed by light energy, the initial energy level (S) increases to level (S) and then decreases to the triplet energy level (T) to effect emission, and thus is evaluated as delayed time fluorescenser. On the other hand, as shown in FIG. 2B, in the present cryptate the increased level (S) decreases to lanthanide energy level (D) via (T) and then effects emission, wherein the energy level (F) is the ground state of lanthanide ion.
The lanthanide ion used in the present invention is any one, though europium, terbium, samarium and dyspridium are desirable in this order due to their emission ability.
The cryptate shown by the FIG. 1 solves the problems seen in the conventional coordination compounds, that is, ease of the release of metal atom from the ligand, the tendency of putting out of the fluorescence emission and the low energy transition efficiency on the ligand.
The novel cryptate of the present invention can be easily prepared by slightly modifying the aforementioned method of Rodriguez et al which is incorporated by reference herein. Thus, the cryptand prepared according to the Rodriguez's method is allowed to react with a strong acid salt of lanthanides such as nitric acid salt. The cryptand and cryptate each having an aromatic ring group such as a phenyl group can also be obtained from the phenanthroline compound.
The cryptate derivative having the functional group can be prepared by introducing a functional group capable of bonding directly or indirectly to a --NH2 group or --SH group at any position of the aromatic ring group contained in the cryptand. By the introduction the cryptate of the present invention can considerably enlarge its use, permitting covalently bonding with a substrate such as a high molecular weight substance having a --NH2 or --SH group, for example, proteins, especially antibodies, a polymer and the like. The combined substance can be used in a fluorescent immunoassay or light modification.
The functional group is selected, for example, from halosulfonyl, haloacetamido, ethyleneiminosulfonyl, maleimido, isothiocyanato groups and the like which can be covalently bonded with amino or sulfhydryl group. An aromatic ring, especially a phenyl group, easily permits the introduction of the functional group. Thus, a cryptate containing a phenyl group substituent is preferable for the purpose.
Also, the functional group may be one capable of bonding to the substrate through a bifunctional compound. Thus, amino group is, for example, selected therefor. The example of the bi-functional compound for amino group is a water soluble carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, glutaraldehyde, or bis-diazotized benzidine. The bonding technique to the substrate is well known as a method of bonding a hapten such as polypeptide to a carrier protein for giving the hapten an antigenicity.
The functional group introduced is sufficient in an amount of 1 per mol of cryptate but may be more. The introduction of the functional group to an aromatic ring of a coordination compound or photoactive compound is well known. For example, C. F. Meares and T. Wensel (Acc. Chem. Res. 1984, 17, pp 202-209) disclose the reduction of (p-nitrobenzyl-ethylenediamine tetraacetic acid to (p-amino-benzyl) compound of which amino group is then converted to a isothiocyanato group by reacting with thiophosgen and to haloacetamido group by haloacetohalide, respectively. Also, J. K. Weltman et al (J. Biol. Chem., vol. 18, May 10 pp 3173-3177) report the preparation of N-(3-pyrene) maleimide by reacting 3-aminopyrene with maleic anhydride to form N-(3-pyrene) maleamic acid which is then cyclized under dehydration by reacting with acetic anhydride to form N-(3-pyrene) maleimide. Further, W. H. Scouten et al (Biochimica et Biophysica Acta, 336, 1977, pp 421-426) report the preparation of N-dansylaziridine by reacting dansyl chloride with ethylenimine in the presence of triethylamine. All of the references are incorporated by reference herein.
In the introduction of functional group, any method including the above methods may be used. However, it is noted that a phenyl group with which phenanthroline is substituted is more easily subjected to such introduction, and the use of phenanthroline compound having a phenyl substituent is desirable.
The introduction of functional group may be effected with respect to phenanthroline or phenylphenanthroline compound itself, cryptand or cryptate thereof. In general, phenanthroline compound or its cryptand would be subjected to such introduction. In case of the former, the number of the functional group would be optionally selectable.
The kind of functional group is suitably selected depending upon the kinds of bonding objective amino or sulfhydryl group in a substrate to be bonded. If the objective high molecular weight substance is an antibody, a halosulfonyl such as chlorosulfonyl group or isothiocyanate group is selected for IgG having an objective amino group in the side chain and a haloacetamide such as iodoacetamide, or ethyleneiminosulfonyl or maleimino group for Fab' having a sulfhydryl group. Also, an amino group is introduced if a bifunctional compound such as glutalaldehyde or others as mentioned above is used for the substrate having a free amino group.
Thus, the present invention provides a functional cryptate derivative of the formula ##STR3## wherein Y is a functional group capable of directly or indirectly bonding to amino or sulfhydryl group, which may be amino, isothiocyanato, halosulfonyl, halo-acetamido, maleimido, ethyleneiminosulfonyl group, or a phenyl group having the same, and the total number of "m" is at least 1 and each "m" is 0, 1 or 2.
An example of the preparation of the present cryptate and its functional derivative from the starting compound of 4,7-diphenyl-2,9-dimethyl-1,10-phenanthroline is shown by the following formula steps: ##STR4##
The present cryptate is soluble in water. The cryptate itself can be used as a wave length modifier in a form embedded in a polymer film, sheet or beads or photo synthesizer. The cryptate derivative having the functional group can be bonded with a variety of high molecular weight substances to form a permanent photoactive material. In particular, an antibody labelled with the present cryptate derivative is usable for delayed time performance fluorescent immunoassay. The labelled antibody is dissolved in water or immobilized on solid as carrier and may be used in immunoassay and affinity chromatography. Also, covalently labelled polymer is usable as a wave length modifying film for ultraviolet ray sensivity in silicon photodiode and CCD camera or as a light absorption film.
The invention is explained in detail by referring to the following Examples which should not be construed to limit the invention defined in the accompanying Claims.
EXAMPLE 1
15 mmol 4,7-Diphenyl-2,9-dimethyl-1,10-phenanthroline (trade name: NEOCUPROINE) and 30 mmol N-bromosuccinimide are dissolved in carbon tetrachloride 150 ml. After the solution is refluxed for 30 minutes 30 mg, benzoyl peroxide is added to the solution, and then reflux is continued for 2 hours. The unreacted succinimide is removed from the reaction liquid by filtration. The resulting solution is dried to obtain 8 mmol 4,7-diphenyl-2,9-dibromomethyl-1,10-phenanthroline.
Thus obtained 2 mmol phenanthroline compound is dissolved in 500 ml of acetonitrile containing 5 mmol of ammonia and refluxed at about 100° C. for 18 hours. The reaction liquid is cooled to a room temperature, filtered and dried to obtain 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-diphenyl-1,10-phenanthroline) in an amount of 6 mmol.
To a solution containing 40 ml trimethy orthoformate 10 ml in acetonitrile is added 0.4 mmol europium nitrate and refluxed for 1 hour in the atomosphere of nitrogen. To the solution is further added a solution of 0.4 mmol 2,2',2",9,9',9"-bis[nitrilotri-(methylene)]tris(4,7-diphenyl-1,10-phenanthroline) in 10 ml of acetonitril and refluxed for 3 hours. After cooling to a room temperature, the reaction liquid is filtered and dried to obtain 0.25 mmol 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-diphenyl-1,10-phenanthroline) europium.
To 2 ml of 97% pure chlorosulfonic acid is added 1.0 mmol of 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-diphenyl-1,10-phenanthroline) europium and the solution is stirred at 80° C. for 4 hours. The reaction liquid is cooled to a room temperature and filtered to obtain 0.95 mmol of 2,2',2",9,9',9"-bis[nitrilotri-(methylene)]tris(4,7-dichlorosulfonylphenyl-1,10-phenanthroline) europium.
EXAMPLE 2
2 mmol 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(4,7-dichlorosulfonylphenyl-1,10-phenanthroline) europium obtained in Example 1 is dissolved in 0.5 ml of ethanol and added drop by drop slowly to a carbonate buffer solution (100 mmol, pH 9.2) containing 0.72 mol bovine serum albumin(BSA). The reaction liquid is subjected to an affinity chromatography using sephadex-5 column to obtain the labelled BSA which is excited by light of 337 nm and confirmed by the fluorescece at 613 nm based on europium ion, by means of a fluorescence photometer.
EXAMPLE 3
Example 1 is repeated to obtain 2,2',2",9,9',9"-bis-[nitrilotri(methylene)]tris (1,10-phenanthroline) europium, provided that 2,9-dimethyl-1,0-phenanthroline is used in place of 4,7-diphenyl-2,9-dimethyl-1, 10-phenanthroline.

Claims (2)

What is claimed is:
1. A protein labelled covalently with a lanthanide complex of europium cryptate of 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline) of the formula ##STR5## wherein Y is a halosulfonyl functional group or Y is a phenyl group containing a halosulfonyl functional group, and wherein the total number of m is at least 1 and each m is 0, 1 or 2, and wherein said protein is bovine serum albumin.
2. The protein according to claim 1, wherein the halosulfonyl functional group is chlorosulfonyl.
US08/051,819 1990-05-07 1993-04-26 Lanthanide cryptate of trisphenanthroline Expired - Fee Related US5286848A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/051,819 US5286848A (en) 1990-05-07 1993-04-26 Lanthanide cryptate of trisphenanthroline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51959490A 1990-05-07 1990-05-07
US08/051,819 US5286848A (en) 1990-05-07 1993-04-26 Lanthanide cryptate of trisphenanthroline

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US51959490A Continuation 1990-05-07 1990-05-07

Publications (1)

Publication Number Publication Date
US5286848A true US5286848A (en) 1994-02-15

Family

ID=26729850

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/051,819 Expired - Fee Related US5286848A (en) 1990-05-07 1993-04-26 Lanthanide cryptate of trisphenanthroline

Country Status (1)

Country Link
US (1) US5286848A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041122A1 (en) * 1996-04-30 1997-11-06 The Regents Of The University Of California 3- and 3,8-substituted 1,10-phenanthrolines and their use in electron and energy transfer processes
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6024937A (en) * 1994-05-19 2000-02-15 Neorx Corporation Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
CN105218570A (en) * 2015-07-30 2016-01-06 中国科学院苏州生物医学工程技术研究所 A kind of lanthanide series compound and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257955A (en) * 1978-10-06 1981-03-24 Board Of Trustees, Michigan State University Lanthanide rare earth series cryptate compounds and process for the preparation of metal cryptates in general
US4772563A (en) * 1984-08-13 1988-09-20 Hsc Research Development Corporation 1,10-phenanthroline derivatives and use in fluorescence immunoassays
US4837169A (en) * 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257955A (en) * 1978-10-06 1981-03-24 Board Of Trustees, Michigan State University Lanthanide rare earth series cryptate compounds and process for the preparation of metal cryptates in general
US4837169A (en) * 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
US4772563A (en) * 1984-08-13 1988-09-20 Hsc Research Development Corporation 1,10-phenanthroline derivatives and use in fluorescence immunoassays

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Agnew. Chem. Int. Ed. Engl. 26 (1987) No. 12, pp. 1266 1267. *
Agnew. Chem. Int. Ed. Engl. 26 (1987) No. 12, pp. 1266-1267.
Rodriguez Ubis et al., Helvetica Chimica Acta vol. 67, pp. 2264 2269 (1984). *
Rodriguez-Ubis et al., Helvetica Chimica Acta-vol. 67, pp. 2264-2269 (1984).
Rudinger, Peptide Hormones, Parson (ed.), U Park Press, Baltimore, pp. 1 7 (1976). *
Rudinger, Peptide Hormones, Parson (ed.), U Park Press, Baltimore, pp. 1-7 (1976).

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024937A (en) * 1994-05-19 2000-02-15 Neorx Corporation Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
WO1997041122A1 (en) * 1996-04-30 1997-11-06 The Regents Of The University Of California 3- and 3,8-substituted 1,10-phenanthrolines and their use in electron and energy transfer processes
US6936700B2 (en) 1997-03-28 2005-08-30 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6177551B1 (en) 1997-03-28 2001-01-23 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6187910B1 (en) 1997-03-28 2001-02-13 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6528627B1 (en) 1997-03-28 2003-03-04 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US20050276754A1 (en) * 1997-03-28 2005-12-15 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US7268220B2 (en) 1997-03-28 2007-09-11 Poniard Pharmaceuticals, Inc. Bridged aromatic substituted amine ligands with donor atoms
US20080227961A1 (en) * 1997-03-28 2008-09-18 Poniard Pharmaceuticals, Inc.. Bridged aromatic substituted amine ligands with donor atoms
US7674886B2 (en) 1997-03-28 2010-03-09 Poniard Pharmaceuticals, Inc. Bridged aromatic substituted amine ligands with donor atoms
CN105218570A (en) * 2015-07-30 2016-01-06 中国科学院苏州生物医学工程技术研究所 A kind of lanthanide series compound and its preparation method and application
CN105218570B (en) * 2015-07-30 2017-05-24 中国科学院苏州生物医学工程技术研究所 Lanthanide-series compound and preparation method and application thereof

Similar Documents

Publication Publication Date Title
US4927923A (en) Macropolycyclic rare earth complexes and application as fluorescent tracers
CA1309016C (en) Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth metal chelate fluorophores
Evangelista et al. A new europium chelate for protein labelling and time-resolved fluorometric applications
EP0195413B1 (en) Substituted pyridine derivatives
CA1292710C (en) Fluorescent labels
JP3117459B2 (en) Method for amplifying luminescence signal from fluorescent compound
US5238808A (en) Luminescent metal chelate labels and means for detection
CA2172145C (en) Metal complexes with a charged linker
US5221605A (en) Luminescent metal chelate labels and means for detection
US4859777A (en) Terpyridine chelating agents
US5981286A (en) Hydrophilic metal complexes
US5262526A (en) Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
US4259233A (en) β-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates
JP5070057B2 (en) Novel fluorescent labeling compounds
CA1102789A (en) Immunological determination
EP1032837B1 (en) Target sequences for synthetic molecules and methods of using same
US5432101A (en) Macropolycyclic rare earth complexes and application as fluorescent tracers
KR0183420B1 (en) Metal complexes with charged linker
US6080839A (en) Labeling reactants and their use
US6395503B1 (en) Chemiluminescent reagents and chemiluminescence analysis methods with the use of the same
US5286848A (en) Lanthanide cryptate of trisphenanthroline
US5998156A (en) Color developing method, enzyme immunoassay using the color developing method, and immunochromatography incorporating the enzyme immunoassay
CA2502959A1 (en) Metal chelates and methods of using them for time-resolved fluorescence
JP2000111480A (en) New labelling reagent
US6951760B2 (en) Diagnostic neodymium(III), ytterbium(III), or erbium(III) ion-ligand complexes

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20020215